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Hypertension
A Han, M Helewa, W Stones, H Nathan, S Miller, LA Magee
DEFINING HYPERTENSION
Defining what represents hypertension in pregnancy 
is complicated by the fact that blood pressure levels 
in pregnancy are even more dynamic than they are 
in non-pregnant women. Blood pressure levels in 
pregnancy vary according to gestational age, and 
the circadian rhythm in women with a hypertensive 
disorder of pregnancy may differ by more than in 
normotensive pregnant women and non-pregnant 
women.
SYNOPSIS
Defining hypertension in pregnancy is challenging because blood pressure levels in 
pregnancy are dynamic, having a circadian rhythm and also changing with advancing 
gestational age. The accepted definition is a sustained systolic (sBP) of 140 mmHg 
or a sustained diastolic blood pressure (dBP) 90 mmHg, by office (or in-hospital) 
measurement.
Measurement of blood pressure in pregnancy should follow standardised methods, 
as outside pregnancy. Blood pressure measurement may occur in three types of settings, 
which will dictate in part, which measurement device(s) will be used. The settings are 
(1) health care facility; and two types of settings outside the facility: (2) ‘ambulatory’ 
blood pressure measurement (ABPM); and (3) home blood pressure measurement 
(HBPM). Furthermore, blood pressure can be measured using auscultatory (mercury or 
aneroid devices) or automated methods.
Factors to consider when selecting a blood pressure measurement device include 
validation, disease specificity, observer error and the need for regular recalibration. The 
accuracy of a device is repeatedly compared to two calibrated mercury sphygmomanometers 
(the gold standard), by trained observers, over a range of blood pressures and for women 
with different hypertensive disorders of pregnancy; only a few devices have been 
validated among women with pre-eclampsia.
This chapter discusses the advantages and/or disadvantages of the various settings 
and devices.
Low- and middle-income countries (LMICs) bear a disproportionate burden of 
maternal morbidity and mortality from the hypertensive disorders of pregnancy. While 
regular blood pressure monitoring can cost-effectively reduce this disparity, LMIC-health 
systems face unique challenges that reduce this capacity. Assessment of service gaps and 
programmatic responses to ensure access to blood pressure measurement are a priority, 
supported where appropriate by implementation research.
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Outside pregnancy, both sBP and dBP peak in 
the afternoon and drop in the evening and during 
the night. However, this pattern tends to be blunted 
in women with gestational hypertension and 
pre-eclampsia among whom it tends to peak in the 
evening and overnight1,2. Proposed theories to 
explain this include a compensatory mechanism to 
maintain organ blood flow during sleep in response 
to ischaemia, or a disturbance in hypothalamic 
pituitary adrenal periodicity and in sympathetic 
nervous system activity3.
Blood pressure tends to reach its nadir during 
pregnancy just before or at 20 weeks’ gestation, 
with some variation by parity. In nulliparous 
women, sBP reaches its nadir at 17 weeks, and dBP 
at 19 weeks. These troughs in blood pressure are 
slightly later in multiparous women – 18 weeks for 
sBP and 20 weeks for dBP4.
Hypertension is defined according to systolic 
and diastolic criteria, with either needing to be 
sustained (i.e., present on repeat measurement): 
sBP 140 mmHg or a dBP 90 mmHg. A dBP of 
90 mmHg represents a level that is both: (1) two 
standard deviations above values at any point 
in normal pregnancy, and (2) associated with 
increased perinatal morbidity in non-proteinuric 
hypertension. Systolic blood pressure is included in 
the definition, recognising that it is more susceptible 
to environmental influences and an inferior 
predictor of adverse pregnancy outcomes than is 
dBP5–7. Furthermore, a focus on sBP is appropriate 
given that inadequate treatment of severe systolic 
hypertension has been recognised as a major failing 
in the care of women who died with pre-eclampsia8. 
A conservative diagnostic approach is particularly 
important where ANC follow-up may be less 
reliable, as illustrated by the following quote:
“If they feel there is any fluctuations or rise in 
blood pressure, immediately they should refer 
to the primary health center or directly refer to 
the gynecologist . . . then the initial proper 
treatment can be started to the hypertension 
with the help of the gynecologist then they can 
continue treatment until delivery.”
Health Administrator, Bagalkot, India
On average, obese women have higher blood 
pressure in each trimester compared with those 
who are not obese, even when an appropriately 
sized cuff is used. The difference is about 10 mmHg 
for sBP and 8 mmHg for dBP4.
The importance of repeat measurement
It is important to remember that blood pressure, 
whether systolic or diastolic, must be confirmed to be 
elevated on repeat measurement before the woman 
can be considered to be hypertensive to reduce the 
potential for misdiagnosis based on a spurious reading 
or the patient’s anxiety during the consultation. The 
first auscultatory measurement should be discarded 
(as the first is in lieu of taking blood pressure by 
palpation), and two additional measurements should 
be taken and averaged to get the blood pressure for 
that visit. Ideally, repeat measurement should be at 
least 15 minutes apart at that visit.
Up to 30–70% of women with an office blood 
pressure of 140/90 mmHg are found to have 
normal blood pressure on subsequent measurements 
on the same visit, or after serial measurement by 
ABPM (i.e., serial measurements by a portable 
recording device over 24 hours) or HBPM (i.e., 
measuring the blood pressure at home)5,9–12. 
Whether the woman is reassessed in hours, days, or 
weeks will depend on the level of the blood 
pressure and the underlying hypertensive disorder 
of pregnancy diagnosed or suspected, as the elevated 
office blood pressure may be owing to a situational 
rise, the ‘white coat’ effect, or early manifestations 
of pre-eclampsia13,14.
Severe hypertension
Severe pregnancy hypertension is defined as sBP 
160 mmHg or a dBP 110 mmHg. The systolic 
value was reduced from 170 mmHg by most 
international societies after recognition that a sBP 
160 mmHg is associated with an increased risk of 
stroke in pregnancy15,16.
KEY POINT
Hypertension in pregnancy is a sustained sBP 
140 mmHg or dBP 90 mmHg by office (or in 
hospital) measurement
KEY POINT
Severe hypertension in pregnancy is a sustained 
sBP 160 mmHg or dBP 110 mmHg
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What is not included in the definition of 
pregnancy hypertension
A relative rise in blood pressure of 30 mmHg in 
sBP or 15 mmHg in dBP is not part of the definition 
of a hypertensive disorder of pregnancy, given that 
it is within the variation seen in all trimesters of 
pregnancy, and there is a high false positive rate if it 
is taken as a diagnostic criterion for pre-eclampsia17.
Mean arterial pressure (MAP) is not part of the 
definition of hypertension in pregnancy as there are 
no clinical studies that relate MAP levels to risk and 
outcomes.
Blood pressure measurements taken in the 
community
Outside pregnancy, a widely accepted threshold 
for normal (daytime) ABPM or HBPM is 
<135/85 mmHg18. As such, a diagnosis of 
hypertension in pregnancy is consistent with a 
daytime ABPM or average HBPM of sBP 
135 mmHg and/or dBP 85 mmHg19,20.
It is recommended that given issues with 
automated blood pressure machines in pregnancy 
and/or self-monitoring techniques, that elevated 
values outside the office be confirmed in the office/
clinic setting. (These issues are discussed in detail 
under blood pressure measurement devices and 
HBPM sections, below.)
There can be discordance between blood 
pressure values taken in the office/clinic compared 
with those taken in the community. When the 
discordance cannot be attributed to the blood 
pressure machine and/or the measurement 
technique, two patterns of discordance are widely 
recognised. ‘White coat’ effect is defined as an 
elevated blood pressure in the health facility (i.e., 
140/90 mmHg), but a normal measurement in 
the community (i.e., average daytime ABPM or 
average HBPM values <135/85 mmHg). ‘Masked’ 
hypertension is defined as a normal blood pressure 
in the health facility (i.e., <140/90 mmHg), but an 
elevated measurement in the community (i.e., 
average daytime ABPM or average HBPM values 
135/85 mmHg). Outside pregnancy, it is widely 
recognised that patients with ‘white coat’ effect are 
at lower, but not baseline, risk of adverse 
cardiovascular outcomes related to hypertension 
(such as cardiac or renal disease)21–28. Also, patients 
with ‘masked’ hypertension (i.e., normal office 
blood pressure but elevated ABPM) are at similar 
cardiovascular risk to patients who are hypertensive 
in both the facility and community settings29,30. 
Both ‘white coat’ effect and ‘masked’ hypertension 
are discussed in detail, along with the implications 
for pregnancy outcome, in Chapter 3.
BLOOD PRESSURE MEASUREMENT 
TECHNIQUE
Blood pressure measurement in pregnancy should 
follow the same standardised technique as outside 
pregnancy18,31,32 and the ‘Best Practice Points’ 
below for recommendations specific to pregnant 
women. In brief, the following steps should be 
taken:
1. The woman must be positioned appropriately: 
seated, still, and with her legs uncrossed, feet 
flat on the floor, and her back resting on the 
back of the chair. Women should be in the 
sitting position that gives a blood pressure 
reading that reflects the true value; supine 
positioning has the potential to cause 
hypotension, and left lateral positioning has the 
potential to give a spuriously low reading, 
because the right arm is frequently elevated 
above the level of the heart during blood 
pressure measurement33.
2. The woman should not talk, read, look at 
her phone/computer, or watch television.
3. The woman’s arm should be resting at the 
level of her heart. This may require use of a 
pillow.
4. The woman should rest for 5 minutes before 
her blood pressure is taken.
5. The blood pressure cuff should be placed 
on the woman’s bare upper arm, and not 
over clothing.
6. The blood pressure cuff must be the right 
size. It must be long enough and wide enough. 
The length should cover two-thirds of the 
distance between her shoulder and elbow; the 
bottom should end up about 1–2 cm above 
the elbow. The width must be such that the 
KEY POINT
A diagnosis of hypertension in pregnancy in a 
community setting is consistent with a daytime 
ABPM or average HBPM of sBP 135 or dBP 
85 mmHg
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inflatable part of the blood pressure cuff should 
go around about 80% of the woman’s upper 
arm where the blood pressure is being 
measured. If the cuff is too small (e.g., a 22–
32 cm cuff used on a 35 cm circumference 
arm), it will overestimate sBP by 7–13 mmHg 
and dBP by 5–10 mmHg.
7. The blood pressure should be measured using 
appropriate technique for the machine in 
use.
a. Use of auscultatory techniques requires 
a stethoscope and special training. Blood 
pressure is taken at least three times, with 
the first measurement discarded as it is the 
range-finding measurement; the second 
and third measurements are taken one 
minute apart and the average is the 
measurement for that visit. Korotkoff 
phase V (marked by the disappearance of 
Korotkoff sounds) should be used for 
designation of dBP; compared to phase IV 
(marked by muffling of Korotkoff sounds); 
identification of phase V is more reliable34 
than that of phase IV and pregnancy 
outcomes are similar when either is used35. 
Korotkoff phase IV should be used for 
dBP only if Korotkoff sounds are audible 
as the dBP level approach 0 mmHg.
b. Use of automated devices requires the 
operator to follow the manufacturer’s 
instructions carefully. Two measurements 
are taken 1 minute apart and the average is 
the measurement for that visit.
Blood pressure measurement devices
Blood pressure can be measured using auscultatory 
devices (mercury, aneroid, or liquid-crystal 
sphygmomanometer) or automated methods. 
Mercury devices have largely been removed from 
clinical areas owing to safety concerns. Table 1.1 
outlines the advantages and disadvantages of 
auscultatory and automated methods36.
Auscultatory methods
Auscultatory methods are used primarily in the 
health facility (i.e., office/clinic or hospital) setting 
(with health care personnel trained to use 
stethoscopes), as discussed below.
Aneroid devices appear to give more variable 
blood pressure readings; one study found that 50% 
of aneroid devices had at least one reading that 
was more than 10 mmHg different from others, 
compared with only 10% of mercury devices37.
The liquid-crystal device is a hybrid 
sphygmomanometer developed as an alternative 
to mercury; in an initial study in pregnancy, 
this hybrid device appears to be accurate and 
may be a reasonable alternative to mercury 
sphygmomanometry (or an automated device)38.
Table 1.1 Blood pressure measurement methods36
Auscultatory methods Automated*
Method Observer uses a stethoscope and a mercury, 
aneroid, or crystal device to directly identify 
Korotkoff sounds reflecting sBP and dBP
Oscillometric: proprietary algorithms use maximal 
oscillations during cuff inflation or deflation to estimate 
sBP and dBP
Ultrasonographic: ultrasound transducer uses Doppler 
principles to estimate sBP and dBP
Advantages Uniformly available in all clinical settings Widely available for purchase at reasonable prices
Avoids observer bias
Disadvantages Observer bias and observer error related to 
external noise or auditory acuity 
Sensitive to physical movement
Comments Mercury devices have been removed from most 
clinical settings
Aneroid devices require recalibration every 2 years
Require validation in pregnancy and pre-eclampsia 
specifically
Most devices used in ABPM or HBPM are oscillometric
ABPM, ambulatory blood pressure monitoring; dBP, diastolic blood pressure; HBPM, home blood pressure monitoring; 
sBP, systolic blood pressure




Automated machines may be used in the office/
clinic, community, or home settings, as discussed 
below. A comprehensive list of automated devices 
approved for HBPM can be found at http://www.
dableducational.org and http://www.bhsoc.org/
default.stm.
When choosing an automated blood pressure 
measurement device, considerations include 
validation, disease specificity, observer error (largely 
eliminated with automated devices), and the need 
for regular recalibration. A key issue is that ideally, 
women who are pregnant or postpartum should 
use devices that are accurate for use in both 
pregnancy and pre-eclampsia. First, detection of 
pre-eclampsia is a major objective of all antenatal 
care as maternal and perinatal complications are 
focused in this group of women. Second, women 
with chronic or gestational hypertension are at 
increased risk of pre-eclampsia39–49; women with 
pre-existing hypertension have an approximately 
20% risk of pre-eclampsia39–43, and women with 
gestational hypertension have a risk as high as 35% 
if they present with gestational hypertension prior 
to 34 weeks44–49. Unfortunately in practice, there 
may be no pregnancy and pre-eclampsia approved 
device available locally in well- or under-resourced 
settings, making calibration a particularly important 
concept to understand (see below).
The accuracy of a device is repeatedly compared 
with two calibrated mercury sphygmomanometers 
(the gold standard), by trained observers, over a 
range of blood pressures and for women with 
different hypertensive disorders of pregnancy. This 
must be done for pregnant women compared with 
non-pregnant subjects, as well as specifically for 
women with pre-eclampsia. Pre-eclampsia is 
associated with decreased vessel wall compliance 
and increased interstitial oedema that can lead to 
under-reading of blood pressure by the algorithm 
used by any given automated device; on average, 
the under-reading is by 5 mmHg in systolic and 
diastolic, although there is wide variation50. A 
device that is accurate for measurement of blood 
pressure in a healthy pregnant woman may be 
inaccurate in a woman with pre-eclampsia.
Although automated blood pressure 
measurement devices will eliminate some observer 
error, only some devices have been validated in 
pregnancy51–53 and in pre-eclampsia, specifically54,55. 
It should be noted that in a randomised controlled 
trial of 220 hypertensive pregnant women, 
approximately 20% of whom had pre-eclampsia, 
management using a mercury sphygmomanometer 
or a validated automated electronic blood pressure 
device (Omron HEM-705CP) was associated with 
similar maternal and fetal outcomes1. If anything, 
severe hypertension was more common in the 
group that had blood pressure measured by the 
automated device, possibly related to a reduction in 
observer error associated with use of an automated 
device.
Recalibration involves comparing readings from 
an aneroid or automated blood pressure machine 
with those taken with a mercury manometer. As 
most mercury manometers have been removed 
from clinical settings around the world, most clinics 
will have available to them only aneroid devices. 
Aneroid devices require the most frequent 
calibration in comparison with automated devices56. 
As the devices that women use will be compared 
with the clinic aneroid device in many settings, it is 
critical to understand that aneroid devices must be 
recalibrated every 2 years against mercury devices, 
usually by the hospital biomedical department; 
this must be arranged separately by practitioners 
with private offices. In under-resourced settings, 
procurement processes will need to be strengthened 
to specify devices that are amenable to calibration 
and adjustment, together with a means of tracking 
device maintenance within health facilities over 
months and years of use.
Blood pressure measurement settings
The settings will drive (in part) the choice of blood 
pressure measurement devices, as discussed above19. 
Table 1.2 outlines which devices are used in which 
settings.
Health facility blood pressure measurement
Health facility blood pressure measurement is 
usually undertaken by a physician, nurse, or other 
trained health care provider in an office, clinic, or 
hospital setting. It involves use of any of the 
aforementioned blood pressure measurement 
devices, although most clinics and hospitals use 
aneroid or automated devices. The potential for 
‘white coat’ effect is reduced when multiple 
readings are taken, using proper technique (see 
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‘Blood pressure measurements taken in the 
community’, above), and by either trained 
non-physician health care providers or using a fully 
automated machine that takes multiple readings57–59.
The fact that health facility blood pressure 
measurements may also be falsely normal in the 
approximately 10% of patients with ‘masked’ 
hypertension60 underscores the need for 
community-measurement, by either ABPM or 
HBPM.
Ambulatory blood pressure measurement
ABPM is a process by which blood pressure 
readings are obtained either in a community setting 
(serially over a 24 hour period using an automated 
measuring device) or by serial blood pressure 
measurements in an obstetric or maternal health 
ambulatory care setting. This could be in a 
specialised day unit where women can be monitored 
over several hours without facility admission, or a 
formal programme in which health care workers 
visit women in their homes.
ABPM has the advantage of reducing errors 
associated with clinic measurements61. Also, ABPM 
in the community provides a more comprehensive, 
actual blood pressure profile of a patient’s blood 
pressure during daily activities and at night during 
sleep during which women with pre-eclampsia 
may have a diminished decrease in their blood 
pressure or an actual rise36. The addition of ABPM 
to health facility measurements may be of particular 
value when women have non-severe hypertension 
in the office or other facility setting and 
pre-eclampsia is not suspected, particularly if office 
blood pressure values are fluctuating.
Pregnant women with elevated office blood 
pressure measurements but normal ABPM (i.e., 
‘white coat’ effect) are at lower risk of adverse 
maternal and perinatal complications such as severe 
hypertension, preterm delivery and admission to 
neonatal intensive care9,49,54,62,63. However, studies 
have demonstrated that ABPM has only modest 
predictive value for adverse outcomes such as severe 
hypertension, preterm delivery and admission to 
the NICU9,19,49,63. Therefore, the service priority is 
to assure comprehensive conventional measurement 
of blood pressure in pregnancy during clinical 
encounters.
Home blood pressure measurement
HBPM is undertaken by the woman in a home 
environment using an automated blood pressure 
device. Several proposed monitoring schedules 
have been recommended. All involve duplicate 
measurements taken at least twice daily over several 
monitoring days18,64. When HBPM values are 
normal but health facility blood pressure is elevated, 
repeated HBPM (or ABPM) are recommended 
outside pregnancy18.
Regardless of the brand of automated device 
used by the woman, or the chosen system of 
measurement (ABPM or HBPM), the woman 
should be educated about the appropriate blood 
pressure monitoring procedures and interpretation 
Table 1.2 Blood pressure measurement devices used in various settings




  Obstetric day unit
  24 hour ABPM – –
 Home – –
ABPM, ambulatory blood pressure monitoring
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of the values recorded, including when and whom 
to call about blood pressure values of concern.
Which is best – ambulatory blood pressure 
measurement or home blood pressure measurement?
In the past two decades, both ABPM and HBPM 
have gained popularity in confirming diagnosis and 
improving blood pressure monitoring, compliance 
with antihypertensive medication, and achievement 
of blood pressure targets27. Evidence from 
cross-sectional studies shows that HBPM and 
ABPM have modest diagnostic agreement65 and 
they are similar in identifying patients with ‘white 
coat’ effect and ‘masked’ hypertension. However, 
HBPM offers some advantages. HBPM is 
economical, comfortable, engages the patient and is 
easy to repeat when disease evolution is suspected, 
a particularly important issue in pregnancy66. Also, 
pregnant women and practitioners prefer HBPM 
to ABPM67; a Canadian survey on the practices 
surrounding the use of ABPM by maternity care 
providers to diagnose hypertension and to rule out 
the ‘white coat’ effect indicated that the majority 
preferred to use HBPM, while only a minority 
used ABPM68. ABPM is less comfortable; up to 
15% of patients enrolled in ABPM may discontinue 
the process because of discomfort69. There is an 
important cautionary note about HBPM, however; 
HBPM values have not been validated against 
adverse pregnancy outcomes, and, to date, no 
randomised trial has assessed the impact of either 
HBPM or ABPM on maternal or perinatal 
outcomes17.
Literature from outside pregnancy suggests that 
addition of ABPM or HBPM to office/clinic 
measurements is cost-effective19,70. However, 
further implementation research will be needed in 
pregnant women before we can be confident that 
the favourable outcomes seen outside pregnancy 
can be generalised to pregnancy.
UNDER-RESOURCED SETTINGS
Regular blood pressure monitoring is an essential, 
cost-effective intervention for early identification 
and management of the hypertensive disorders of 
pregnancy71. Regular blood pressure monitoring 
may reduce the burden of maternal morbidity and 
mortality from the hypertensive disorders of 
pregnancy that disproportionately affect women in 
LMICs72–75. The obvious priority is the availability 
of functioning equipment to measure blood 
pressure. Additional challenges to address include a 
lack of good quality antenatal care, inadequate 
staffing of health facilities, and gaps in health care 
worker competency.
Availability of equipment in good repair
A service challenge in many LMIC health facilities, 
including maternity wards, is poorly functioning or 
absent equipment that prevents health care workers 
from taking blood pressure measurements (or those 
that are accurate) and acting on the results71,76,77. 
For example, the Malawi Demographic Health 
Survey (DHS) reports that only 64% of health 
centres offering ANC services were equipped with 
blood pressure measurement apparatus78. The 
following quotes serve to further highlight this 
from the perspectives of both health care workers 
and women:
“You must make equipment available, like the 
sphygmomanometer, just ordinary sphyg . . . is 
not available until a patient just throws a fit that 
you know that the problem is high. So, making 
sure simple, simple, things that can save life 
are available, like I said sometimes, the 
sphygmomanometer to monitor blood pressure 
. . .”
Focus Group Discussion participant from 
SOGON (Society of Gynaecology & 
Obstetrics of Nigeria (SOGON)
“Even sometimes you find out that in a health 
center that there is no appropriate instrument 
to take blood pressure. You get to a primary 
health centre and find out that there is 
nothing.”
Focus Group Discussion participant from 
SOGON (Society of Gynaecology & 
Obstetrics of Nigeria (SOGON)
There are several novel technologies that may 
improve access to accurate blood pressure 
measurement at community and health facility 
levels80,81,83–87:
1. A semi-automated blood pressure device and vital 
signs early warning tool 83–85 This device is 
unique for many reasons, most importantly 
because it is one of a few to be accurate in 
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pregnancy and pre-eclampsia, and it is the only 
device known to be accurate at the low blood 
pressure values seen commonly in pregnancy. 
The ‘traffic light’ early warning system alerts 
untrained health care workers to the need for 
urgent intervention and referral of women 
with hypertension or shock (secondary to 
obstetric haemorrhage or sepsis), even if the 
vital sign thresholds are not well understood by 
that health care worker. In addition, the device 
achieves the criteria stipulated by WHO for 
use of automated devices in low-resource 
settings. These features include the following: 
(a) reliance on manual inflation (deflating 
automatically), limiting the power 
requirements; (b) use of sealed lithium batteries 
that are charged through a micro-USB port, a 
method that is ubiquitous even in low-resource 
settings; and (c) the low cost of only $19 USD. 
The device is being evaluated at both 
community- and institutional-levels in a 
number of LMIC sites; qualitative evaluation 
to date of both trained and untrained health 
care users has been overwhelmingly positive. A 
randomised controlled trial is underway to 
assess the ability of the device to reduce 
maternal mortality and morbidity in 
under-resourced settings.
2. An interface connecting blood pressure devices to 
mobile smartphone and tablet technology86 This 
technology is currently under development. 
An audio-based interface allows for blood 
pressure readings (amongst other vital signs) to 
be automatically recorded for tracking and 
trending. Furthermore, there is potential for 
further transmission of advice from a central 
facility to minimally trained health care 
workers based on the blood pressure values.
3. A solar panel-powdered blood pressure device87 A 
semi-automated blood pressure device designed 
for under-resourced settings charges using a 
solar panel and fulfills other WHO criteria for 
use of devices in LMICs. Furthermore, 
qualitative evaluation has demonstrated 
acceptability by non-physician health care 
workers. Although the device has been 
validated as accurate for use in a non-pregnant 
population, it has not been validated for use in 
pregnancy, and so cannot be used in a pregnant 
population at the current time.
In summary, the current priority is the procurement, 
distribution and maintenance of standard blood 
pressure apparatus of robust manufacture that can 
withstand heavy use. Innovative blood pressure 
measurement devices for low-resource settings 
have great potential to reduce maternal mortality 
from pre-eclampsia and eclampsia in LMICs. With 
an emphasis on task-sharing, blood pressure 
measurement devices must not rely on knowledge 
of proper auscultation with a stethoscope in order 
that more workers can use the devices correctly 
(Figure 1.1). Investments will be needed to realise 
the potential of these technologies88, particularly 
if a focus is placed on implementation in the 
community89.
Quality antenatal care
The provision of good quality ANC is an 
evidence-based intervention that reduces maternal 
and neonatal mortality and morbidity, particularly 
in LMICs90,91. The quality of ANC is measured by 
three dimensions: number of visits, timing of 
initiation of care, and inclusion of all recommended 
components of care90.
Number of antenatal care visits
Compared to a country’s defined standard care, 
attending a reduced number of antenatal visits is 
associated with an increase in perinatal mortality92. 
Globally, only 64% of pregnant women receive the 
Figure 1.1 Taking blood pressure in the primary health 
centre with an automated device
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recommended minimum of four ANC visits in 
pregnancy93. A disproportionate number of these 
women reside in LMICs, such as rural Nigeria 
where only 39% of pregnant women were found to 
attend four or more ANC visits94. However, this 
pattern of fewer than recommended ANC visits has 
also been reported in inner city women in 
high-income countries95.
Timing of initiation of care
Despite WHO recommendations to start ANC 
within the first 4 months of pregnancy, on a global 
scale, many women start ANC in the second or 
third trimester96. This is a particular issue in 
sub-Saharan Africa96, such as in Tanzania where the 
median month of first visit for ANC was 5.5 
months97. However, unsatisfactory patterns of care 
are also reported by other developing countries, 
such as Cambodia where the Cambodian 
Demographic Health Survey found that 30% of 
women who received ANC started that care in the 
second trimester98.
Inclusion of all recommended components of care
The critical importance of inclusion of blood 
pressure in ANC is illustrated by the following 
quote:
“Eclampsia doesn’t happen frequently without 
pre-eclampsia and the way to know that, first, 
is the blood pressure”
Focus Group Discussion participant from 
Society of Gynaecology & Obstetrics of 
Nigeria (SOGON)
Blood pressure measurement (and urine testing for 
proteinuria) is a key component of ANC that has as 
a primary aim, the detection of pre-eclampsia90. 
Although blood pressure measurement is one of 
the more commonly received components of ANC 
in LMICs90,99,100, many women still do not have 
their blood pressure measured91,100,101 and there is 
variability in rates of measurement from country to 
country. According to Demographic Health Survey 
publications, the proportion of women receiving 
ANC who have their blood pressure measured is 
>90% in Cambodia and Ghana, just over 85% in 
Nepal, Pakistan and Rwanda90,98,102–104, but only 
53% in Laos105 and variable in many African 
countries (i.e., 75% in Malawi78, 52.5% in Uganda96 
and 40% in Kenya106).
Continued efforts are required to improve 
access to quality ANC. Predictors of women’s 
attendance at four or more ANC visits and receipt 
of good quality ANC have been identified and are 
listed in Table 1.390,107. Included among these 
characeristics are higher maternal education and 
higher household economic status. It follows from 
this information that interventions that aim to 
reduce maternal and perinatal morbidity and 
mortality from pre-eclampsia may focus in the 
short-term on targeting women at higher risk, such 
as those with lower levels of education and lower 
socioeconomic status. A sustainable longer-term 
intervention will require a multi-sectoral approach 
involving entire communities, including 
governments and policy-makers with the aim of 
improving access to education by girls and women 
and reducing economic inequalities90. However, to 
generate confidence in the health system and 
appropriate demand for services, women must be 
assured that each and every antenatal attendance 
will lead to provision of the essential components 
of care, such as blood pressure measurement 
using a correct technique and with functional 
equipment.
Health care worker staffing
The challenges of measuring blood pressure may 
be compounded by an inadequate number of 
health care workers and/or a lack of their training 
to measure blood pressure using appropriate 
technique. Inadequate staffing numbers can strain 
the ability of a facility to diagnose pre-eclampsia, 
KEY POINT
Blood pressure measurement is one of the more 
commonly received components of ANC in 
LMICs, but estimates vary from country to 
country
KEY POINT
WHO recommends that the first ANC visit be 
within the first 4 months of pregnancy
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whether during ANC visits in an overcrowded 
health centre, or monitoring women in labour on 
a maternity ward. Although task-shifting to the 
community level and use of automated devices 
may address some service access gaps, the emphasis 
needs to be on functionality across the levels of the 
health system whether under government authority 
or other initiatives77. Interventions to improve 
health worker training and maintenance of 
competency for good maternity care are 
needed99,101. Appendix 1.1108,109 contains an 
example of material used to train community 
health care workers to take blood pressure using 
the Microlife 3AS1-2 semi-automated blood 
pressure device (Figure 1.2).
Table 1.3 Factors associated with better access to antenatal care (ANC)





Higher household economic status
Non-smokers
Women have a say in decision-making
Higher paternal education
Maternal occupation other than agriculture
Urban residence
Exposure to general media
Characteristics of ANC
Receiving ANC from a skilled provider
Receiving ANC in a hospital
F igure 1.2 Taking blood pressure in the community 




(Please see Appendix 1.2 for the evaluation of the strength of the recommendation and the quality of the 
evidence on which they are based.)
Diagnosis of hypertension
1. The diagnosis of hypertension should be confirmed by health facility blood pressure measurements.
2. Hypertension in pregnancy should be defined as a sBP 140 mmHg and/or dBP 90 mmHg, based 
on the average of at least two measurements, taken at least 15 minutes apart, using the same arm.
3. For the purposes of defining superimposed pre-eclampsia in women with pre-existing hypertension, 
‘resistant hypertension’ should be defined as the need for three antihypertensive medications for 
blood pressure control at 20 weeks’ gestation.
4. A ‘transient’ hypertensive effect should be defined a sBP 140 mmHg or a dBP 90 mmHg which 
is not confirmed on the same visit after the woman rests, or on subsequent visits.
5. A ‘white coat’ hypertensive effect refers to blood pressure that is elevated in a health facility (i.e., 
sBP 140 mmHg or dBP 90 mmHg) but by ABPM or HBPM, sBP is <135 mmHg and dBP is 
<85 mmHg.
6. ‘Masked’ hypertension refers to blood pressure that is normal in a health facility (i.e., sBP <140 mmHg 
and dBP <90 mmHg) but elevated by ABPM or HBPM (i.e., sBP of 135 mmHg or dBP 
85 mmHg).
7. Severe hypertension should be defined as a sBP of 160 mmHg or a dBP of 110 mmHg based on 
the average of at least two measurements, taken at least 15 minutes apart, using the same arm. This 
finding should prompt urgent intervention to control the blood pressure.
Blood pressure measurement
1. Blood pressure should be measured using standardised technique, particularly with the woman 
seated and her arm at the level of the heart.
2. An appropriately sized cuff (i.e., length of 1.5 times the circumference of the arm) should be used.
3. Korotkoff phase V (marked as disappearance of Korotkoff sounds) should be used to designate dBP.
4. If blood pressure is consistently higher in one arm, the arm with the higher values should be used 
for all blood pressure measurements.
5. Blood pressure can be measured using a mercury sphygmomanometer, calibrated aneroid device, or 
an automated device that has been validated for use in pre-eclampsia.
6. Automated blood pressure machines that have not been validated for use in pre-eclampsia may 
under- or over-estimate blood pressure in those women, so those readings should be compared with 
those using mercury sphygmomanometry or a calibrated aneroid device.
7. In the health facility setting, when blood pressure elevation is non-severe and pre-eclampsia is not 
suspected, ABPM or HBPM is useful to confirm persistently elevated blood pressure.
8. When HBPM is used, maternity care providers should ensure that women have adequate training 
in measuring their blood pressure and interpreting the readings taken.
9. The accuracy of all blood pressure measurement devices used in health facilities should be checked 
regularly (e.g., annually) against a calibrated device.
10. The accuracy of all automated devices used for HBPM should be checked regularly against a 
calibrated device (e.g., at multiple ANC for an individual woman).
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PRIORITIES FOR UNDER-RESOURCED 
SETTINGS
Table 1.4 outlines priorities for under-resourced 
settings. Unlike most diagnostic or therapeutic 
interventions in the area of hypertensive disorders 
of pregnancy, measurement of blood pressure and 
diagnosis of hypertension have more priorities at 
the community rather than the facility level. A 
sample policy brief that focuses on blood pressure 
measurement is contained in Appendix 1.3.
WHAT INTERNATIONAL GUIDELINES 
SAY (APPENDIX 1.4)
Abbreviations for Clinical Practice Guidelines are 
ACOG (American College of Obstetricians and 
Gynecologists)110, AOM (Association of Ontario 
Midwives), NICE (National Institutes of Clinical 
Excellence)111, NVOG (National Obstetrics and 
Gynaecology Society, Netherlands)112, PRECOG 
(Pre-eclampsia Community Guideline)119, 
PRECOG II (Pre-eclampsia Community 
Guideline II)120, QLD (Queensland, Australia)113,114, 
SOGC (Society of Obstetricians and Gynaecologists 
of Canada)115, SOMANZ (Society of Obstetric 
Medicine of Australia and New Zealand)116, WHO 
(World Health Organization)117.
In a review of international clinical practice 
guidelines on the hypertensive disorders of 
pregnancy118, nine guidelines stated that pregnancy 
hypertension was defined by both sBP and dBP 
together (140/90 mmHg) (QLD, NICE, NVOG, 
ACOG, SOGC, SOMANZ 2014), or dBP alone 
(90 mmHg) (PRECOG, PRECOG II, AOM); 
no definition is offered by the WHO guidelines. 
Eight of 10 guidelines define severe hypertension, 
seven as blood pressure 160/110 mmHg (NICE, 
QLD, NVOG, AOM, ACOG, SOGC, SOMANZ) 
and one as 170/110 mmHg (PRECOG II); one 
document specifies that severe hypertension 
requiring urgent treatment is 170/110 mmHg 
(SOMANZ 2014).
Table 1.4 Priorities for under-resourced settings
Antepartum & postpartum
Initial priority Ultimate goal
Community
Primary health care centre
(detect, stabilise and refer)
Availability of BP measurement devices Availability of BP measurement devices
Measurement of BP
at each ANC and PNC visit
Measurement of BP
at each ANC and PNC visit
Training and re-training of health workers with 
regards to appropriate BP measurement technique
Training of community health care workers to 
take BP at home visits
Facility
Secondary-level facility
(detect, manage and refer if 
necessary)
Availability of BP measurement devices Availability of BP measurement devices
Measurement of BP
at each ANC and PNC visit
Measurement of BP
at each ANC and PNC visit
Training and re-training of health workers with 
regards to appropriate BP measurement technique
Tertiary-level (referral) 
facility (detect and manage 
definitively)
Availability of BP measurement devices Availability of BP measurement devices
Measurement of BP
at each ANC and PNC visit
Measurement of BP
at each ANC and PNC visit
Training and re-training of health workers with 
regards to appropriate BP measurement technique
ANC, antenatal care; BP, blood pressure; PNC, postnatal care
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PRIORITIES FOR FUTURE RESEARCH
These cover care in well- and under-resourced settings, 
particularly as mercury sphygmomanometers have 
been removed from the vast majority of health 
facilities internationally, and their most common 
replacement, aneroid devices, are not as accurate 
and require regular calibration. An alternative 
to mercury manometry is needed. Low-cost, 
energy-efficient and robust automated blood 
pressure machines are needed for use in LMICs, in 
order that women have blood pressure measured 
(and accurately) as part of high-quality ANC. Also, 
further research is needed into the usefulness of 
HBPM in the ANC of all women, to detect and 
manage the hypertensive disorders of pregnancy. 
Implementation research on which cadres of health 
care workers, including community health workers, 
can accurately use the automated devices will 
enhance task sharing at facilities and in the 
community.
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